Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Thornburg Equity Income Builder Fund Matt Burdett, Christian Hoffmann, Brian McMahon | “Global health & hygiene product producer. +8.8% in 1H 2026, -23.0% in calendar 2025. Dividend yield 4.65% at 30 Jun 2026 price. 5-year local currency dividend growth rate +2.8%/year. Most positive equity contributor to quarterly performance.” | BULL | Q2 2026 Jul 17, 2026 | View Pitch |
Heartland Mid Cap Value Fund Colin McWey, Will Nasgovitz, Troy McGlone | “One holding that ran into difficulties last quarter is Kimberly Clark (KMB), the tissue company behind well-known brands such as Huggies, Cottonelle, and Kleenex. The consumer products giant saw its shares fall more than 14% in November, not because of poor results or sub-par execution. Instead, the stock sank immediately after KMB announced its $48.7 billion acquisition of Kenvue, the consumer health company spun off from Johnson & Johnson which sells Tylenol, Neutrogena, Band-Aid and Listerine. We disagree with management's capital allocation decision, as it takes KMB into new categories and poses significant integration risk. We find it unfortunate that management made such an aggressive move after executing well against an internally focused playbook that positioned KMB for value creation in the coming years. We fear that the Kenvue deal makes the company “bigger, not necessarily better”. We trimmed the position in response to the Kenvue announcement. However, we balance deal-related question marks against a valuation of 13 times earnings (a historically wide discount to peers), better market share trends and improved margin performance in recent years. BSD Analysis: Kimberly-Clark is staples defense: diapers, tissue, and hygiene with steady demand and limited excitement. The moat is shelf space, scale manufacturing, and brand trust, but private label keeps pricing power honest. Inflation periods make the P&L look heroic; later, volumes tell the truth. The failure mode is margin squeeze from pulp/input costs plus consumers trading down. Growth is modest, so capital allocation and cost discipline matter more than “innovation.” The bull case is stable cash flow and buybacks in a volatile macro. The bear case is a value trap if structurally low growth meets multiple compression. KMB is a bond substitute with operational risk. You buy it for stability—just don't expect surprises.” | BEAR | Q4 2025 Dec 31, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
